Immunoprecise Antibodies Ltd
XTSX:IPA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (5.5), the stock would be worth CA$6.5 (0% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.5 | CA$6.5 |
0%
|
| 3-Year Average | 5.5 | CA$6.5 |
0%
|
| 5-Year Average | 5.5 | CA$6.5 |
0%
|
| Industry Average | 5.5 | CA$6.5 |
0%
|
| Country Average | 1.7 | CA$1.98 |
-70%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
161.4m CAD | 5.5 | -9.4 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 84.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.7B USD | 1.9 | 25.1 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.7B USD | 1.8 | 34.1 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 5.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
329.9B CNY | 5.1 | 17.3 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.1B CHF | 2 | -118.7 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.5B USD | 3.1 | 24.2 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.5B USD | 6.6 | 44.3 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27B USD | 1.6 | 19.5 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | 8 | 28.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1 |
| Median | 1.7 |
| 70th Percentile | 3.7 |
| Max | 95 179.6 |
Other Multiples
Immunoprecise Antibodies Ltd
Glance View
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The company is headquartered in Vancouver, British Columbia and currently employs 73 full-time employees. The firm is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company’s Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The firm offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-express proteins, Fc-fusion proteins and bispecific antibodies.
